Early Time Course of Symptom Improvement With Remibrutinib in Chronic Spontaneous Urticaria: Pooled Post Hoc Analyses of the REMIX ‐1/2 Phase 3 Studies
Abstract
Summary We undertook a post hoc, sponsor‐funded analysis of data from two recent clinical trials in CSU. Remibrutinib numerically improved CSU symptoms at 12 h; meaningful effects persisted from Day‐2 through Week‐52.
// Source
Authors: Gordon Lloyd Sussman, Nadine Chapman‐Rothe, Tao Ding, Atsushi Fukunaga, Ana Maria Giménez‐Arnau, Michihiro Hide, Mark Lebwohl, P.G.P Machado, E.D. Martzloff, Giselle S Mosnaim, Christine-Elke Ortmann, Petra Staubach, Hui Tang, Ansgar J. Weyergraf, Bin Yang, John Reed
Institutions: Icahn School of Medicine at Mount Sinai, Fudan University, University of Toronto, Southern Medical University, Universitat Pompeu Fabra, Shanghai Medical College of Fudan University, Hiroshima University, Novartis (Switzerland), Huashan Hospital, University Medical Center of the Johannes Gutenberg University Mainz, Churchill Hospital, Osaka Medical and Pharmaceutical University, Hiroshima City Hiroshima Citizens Hospital, Leiber (Germany)